Living Cell Technologies

About:

Living Cell Technologies develops insulin producing porcine pancreatic islets for the treatment of type 1 diabetes.

Twitter/X: lctglobal

Description:

LCT is a cell-based biotechnology developing insulin producing porcine pancreatic islets for the treatment of type 1 diabetes . LCT's lead product, DIABECELL is in Phase II clinical trial. LCT's encapsulation technology immunoisolates cells and allows cell implants without the use of immunosuppressive drugs.

Total Funding Amount:

$6.28M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Manukau City, Auckland, New Zealand

Founded Date:

1987-01-01

Contact Email:

info(AT)lctglobal.com

Founders:

Robert Elliott

Number of Employees:

1-10

Last Funding Date:

2011-01-18

IPO Status:

Public

Industries: